ATE399000T1 - Antidiabetes-zubereitung zur oralen verabreichung - Google Patents

Antidiabetes-zubereitung zur oralen verabreichung

Info

Publication number
ATE399000T1
ATE399000T1 AT05020892T AT05020892T ATE399000T1 AT E399000 T1 ATE399000 T1 AT E399000T1 AT 05020892 T AT05020892 T AT 05020892T AT 05020892 T AT05020892 T AT 05020892T AT E399000 T1 ATE399000 T1 AT E399000T1
Authority
AT
Austria
Prior art keywords
preparation
antidiabetes
oral administration
prandi
oral anti
Prior art date
Application number
AT05020892T
Other languages
English (en)
Inventor
Chisato Makino
Haruo Orita
Nobutaka Ninomiya
Hidetoshi Sakai
Akira Yabuki
Nobuo Kato
Shigeru Shioya
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26582645&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE399000(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of ATE399000T1 publication Critical patent/ATE399000T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT05020892T 1999-12-28 2000-12-27 Antidiabetes-zubereitung zur oralen verabreichung ATE399000T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP37495999 1999-12-28
JP2000085159 2000-03-24

Publications (1)

Publication Number Publication Date
ATE399000T1 true ATE399000T1 (de) 2008-07-15

Family

ID=26582645

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00985918T ATE310507T1 (de) 1999-12-28 2000-12-27 Orale zusammensetzungen für diabetes
AT05020892T ATE399000T1 (de) 1999-12-28 2000-12-27 Antidiabetes-zubereitung zur oralen verabreichung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00985918T ATE310507T1 (de) 1999-12-28 2000-12-27 Orale zusammensetzungen für diabetes

Country Status (22)

Country Link
US (2) US7022339B2 (de)
EP (2) EP1616561B1 (de)
JP (2) JP4822039B2 (de)
KR (1) KR20020063282A (de)
CN (1) CN1437483A (de)
AT (2) ATE310507T1 (de)
AU (1) AU2226901A (de)
BR (1) BR0016801A (de)
CA (1) CA2395993A1 (de)
CZ (1) CZ20022294A3 (de)
DE (2) DE60024320T2 (de)
ES (2) ES2248159T3 (de)
HK (1) HK1049622A1 (de)
HU (1) HUP0204109A3 (de)
IL (1) IL150294A0 (de)
MX (1) MXPA02006443A (de)
NO (1) NO20023035L (de)
PL (1) PL356300A1 (de)
PT (1) PT1616561E (de)
RU (1) RU2002120498A (de)
SK (1) SK9292002A3 (de)
WO (1) WO2001047557A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4822039B2 (ja) 1999-12-28 2011-11-24 味の素株式会社 経口投与用糖尿病薬製剤
SK14922002A3 (sk) * 2000-03-17 2003-04-01 Ajinomoto Co., Inc. Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru
MXPA03003483A (es) * 2000-10-18 2003-07-14 Ajinomoto Kk Procedimiento para la preparacion de acilfenilalaninas.
JP4114200B2 (ja) * 2000-10-18 2008-07-09 味の素株式会社 ナテグリニド結晶の製造方法
DE60138476D1 (de) * 2000-10-24 2009-06-04 Ajinomoto Kk Nateglinid enthaltende hydrophile arzneimittelpräparate
CA2426745C (en) * 2000-10-24 2009-09-15 Ajinomoto Co., Inc. Methods for producing nateglinide b-type crystals
WO2002034254A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Preparations contenant du nateglinide
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
CN1247194C (zh) * 2002-08-27 2006-03-29 石药集团中奇制药技术（石家庄）有限公司 一种那格列奈包合物
EP1537880A4 (de) * 2002-09-11 2009-07-01 Takeda Pharmaceutical PRûPARAT MIT VERZ GERTER FREISETZUNG
EP1562557B2 (de) 2002-11-01 2016-11-16 University of Medicine and Dentistry of New Jersey Geodenförmige darreichungsform
WO2005013964A1 (ja) 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
WO2005016315A1 (en) * 2003-08-14 2005-02-24 Ranbaxy Laboratories Limited Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
US7611693B2 (en) * 2003-09-17 2009-11-03 Board Of Regents, The Univerisity Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
US20070219250A1 (en) * 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
WO2005094812A1 (ja) * 2004-04-01 2005-10-13 Ajinomoto Co., Inc. ナテグリニド含有製剤
CN100455279C (zh) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 口服延迟释放锭剂组成物及其制法
KR101340946B1 (ko) * 2004-08-04 2013-12-13 알자 코포레이션 오름차 0차 방출 패턴을 나타내는 약물의 서방성 조성물,상기 조성물을 제조하는 방법
WO2006016602A1 (ja) * 2004-08-10 2006-02-16 Ajinomoto Co., Inc. 苦味の低減したナテグリニド含有製剤
CN1660064B (zh) * 2004-12-28 2010-09-29 中山大学 那格列奈自乳化释药***
JP4974057B2 (ja) * 2005-01-31 2012-07-11 味の素株式会社 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
JP6042330B2 (ja) * 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時／遅延放出送達システム
WO2013077819A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Pharmaceutical formulations comprising nateglinide
US20180050096A1 (en) * 2015-02-09 2018-02-22 Entera Bio Ltd. Treatment of hypoparathyroidism
CN107296954A (zh) * 2017-06-09 2017-10-27 王丛飞 一种层粘连蛋白创面保护膜

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US124191A (en) * 1872-02-27 Improvement in woven felted fabrics for bonnets
IT1226940B (it) * 1988-09-16 1991-02-22 Recordati Chem Pharm Sistema terapeutico a rilascio controllato per formulazioni farmaceutiche liquide
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
JP3949725B2 (ja) * 1996-07-17 2007-07-25 オーソーペディック デザインズ，インコーポレイティド 外科用留め具組立体
KR100343062B1 (ko) * 1996-11-15 2002-07-02 에가시라 구니오 정제 조성물
JPH10231242A (ja) * 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk 持続性ジクロフェナクナトリウム組成物
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
CN1158071C (zh) * 1997-05-30 2004-07-21 渗透有限公司 多层渗透装置
ZA985126B (en) * 1997-06-13 1998-12-14 Novo Nordisk As Novel niddm regimen
JPH11130696A (ja) * 1997-08-27 1999-05-18 Takeda Chem Ind Ltd 経口徐放性製剤
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
DE19860698A1 (de) * 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
JP3691685B2 (ja) * 1999-06-22 2005-09-07 株式会社バイオックス 血糖値上昇抑制剤
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
JP4822039B2 (ja) 1999-12-28 2011-11-24 味の素株式会社 経口投与用糖尿病薬製剤
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
WO2002034254A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Preparations contenant du nateglinide
DE60138476D1 (de) * 2000-10-24 2009-06-04 Ajinomoto Kk Nateglinid enthaltende hydrophile arzneimittelpräparate
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration

Also Published As

Publication number Publication date
CA2395993A1 (en) 2001-07-05
DE60024320D1 (de) 2005-12-29
PL356300A1 (en) 2004-06-28
ES2248159T3 (es) 2006-03-16
PT1616561E (pt) 2008-07-09
MXPA02006443A (es) 2002-11-29
IL150294A0 (en) 2002-12-01
US7022339B2 (en) 2006-04-04
NO20023035L (no) 2002-08-21
CN1437483A (zh) 2003-08-20
NO20023035D0 (no) 2002-06-21
CZ20022294A3 (cs) 2002-11-13
HUP0204109A2 (en) 2003-05-28
US20030021843A1 (en) 2003-01-30
DE60024320T2 (de) 2006-08-10
EP1258249A1 (de) 2002-11-20
EP1616561A1 (de) 2006-01-18
EP1258249A4 (de) 2003-03-19
AU2226901A (en) 2001-07-09
WO2001047557A1 (fr) 2001-07-05
US7488498B2 (en) 2009-02-10
ATE310507T1 (de) 2005-12-15
BR0016801A (pt) 2002-09-24
HK1049622A1 (zh) 2003-05-23
EP1258249B1 (de) 2005-11-23
DE60039315D1 (de) 2008-08-07
SK9292002A3 (en) 2002-10-08
ES2305977T3 (es) 2008-11-01
HUP0204109A3 (en) 2004-06-28
JP2011153157A (ja) 2011-08-11
KR20020063282A (ko) 2002-08-01
RU2002120498A (ru) 2004-04-10
JP4822039B2 (ja) 2011-11-24
EP1616561B1 (de) 2008-06-25
US20060029669A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
ATE399000T1 (de) Antidiabetes-zubereitung zur oralen verabreichung
DE69831421D1 (de) Zusammensetzungen zur nasalen verabreichung
DE69909135D1 (de) Orale zubereitung zur bekämpfung von mundgeruch
ATE392863T1 (de) Streifen zur abgabe eines mundpflegewirkstoffes
DE69936002D1 (de) Angepasster löffel zur oralen medikamenten-verabreichung
EE05581B1 (et) Aripiprasooli ravimlahus peroraalseks manustamiseks
AU1227601A (en) Breakaway devices for stabilizing dental casts
DE60041069D1 (de) Positioniervorrichtung zur transversalen zahnärztlichen röntgentomographie
AU2737801A (en) Tip for dental flossing device
AU2001256201A1 (en) Device for administering implants
DE69807768T2 (de) Rapamycin enthaltende Formulierungen zur oralen Verabreichung
DE60119354D1 (de) Spritze zur Dentalanästhesie
NO20034556D0 (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60237018D1 (de) Mikroröhrchen zur therapeutischen abgabe
DE60019859D1 (de) Dentales Winkelhandstück
ATE283687T1 (de) Rapamycin-formulierungen zur oralen verabreichung
AU1660401A (en) Tip for dental flossing device
ITMI991641A0 (it) Dispositivo per impianto dentale
ATE272367T1 (de) Zahnimplantat
ITMO990002A0 (it) Articolatore per odontotecnica.
AU2001278335A1 (en) Equine dental speculum
AU3620800A (en) Dental articulator
TW521569U (en) Device for controlling mouth of animal
AU2002247475A1 (en) Articulator for dental casts
FR2790382B1 (fr) Articulateur dentaire

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties